Helix vs Tempus
Two genomics companies selling to health systems with different units of value. Helix is population infrastructure: sequence a population once, hold the data as an institutional asset, and return to it for clinical and research questions over years. Tempus sells the software layer around oncology care, decision support that flags patients drifting off guideline treatment, built on data its own laboratory produces, with the most complete health privacy disclosure in this category. The decision follows the ambition. A system enrolling a population and planning to reuse those genomes for a decade is buying what Helix sells, and inherits a consent problem it must solve before the first sample, because a genome cannot be un shared once it is out.
- It is population scale infrastructure, with institutions running programmes on it and returning to the same sequence for later clinical and research questions.
- Sequence once and reuse changes the economics of genomics from a per test cost into an asset the institution holds.
- The interoperability position is oriented to enterprise deployment rather than to a laboratory workflow.
- The provider software is the product, with oncology decision support and physician tooling built on data its own laboratory generates.
- The health privacy disclosure is the most complete in this category, covering both the laboratory and the software roles.
- For an oncology programme the question is what happens between tests, and that is what the software addresses.
Side by Side
| Axis | H Helix |
T Tempus |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Diagnostics & Genomics page.
Population genomics raises a consent problem this comparison should not skip: a sequence generated once and reused for future purposes requires a consent model that anticipates uses not yet defined, and a participant cannot revoke a genome once shared. Ancestral representation applies to both, since interpretation quality depends on reference data drawn disproportionately from European ancestry populations. Neither publishes pricing in a comparable form, and the commercial shapes differ enough, per programme against per test and per seat, that a like for like figure will not exist.